No headlines found.
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
Globe Newswire (Mon, 12-Feb 8:00 AM ET)
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
Acasti Pharma - Class A trades on the NASDAQ stock market under the symbol ACST.
As of May 9, 2024, ACST stock price declined to $2.76 with 9,008 million shares trading.
ACST has a beta of 0.29, meaning it tends to be less sensitive to market movements. ACST has a correlation of 0.00 to the broad based SPY ETF.
ACST has a market cap of $25.94 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ACST stock traded as high as $32.64 and as low as $1.72.
The top ETF exchange traded funds that ACST belongs to (by Net Assets): KRUZ.
ACST has underperformed the market in the last year with a price return of 0.0% while the SPY ETF gained +27.7%. However, in the short term, ACST had mixed performance relative to the market. It has outperformed in the last 3 months, returning +12.7% vs +4.7% return in SPY. But in the last 2 weeks, ACST shares have been beat by the market, returning -4.8% compared to an SPY return of +2.9%.
ACST support price is $2.69 and resistance is $3.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACST stock will trade within this expected range on the day.